Signs Agreement with London School of Hygiene & Tropical Medicine
Sydney, Mar 9, 2016 AEST (ABN Newswire) - The Directors of InvitroCue Limited (
ASX:IVQ) ("InvitroCue" or "the Company") are pleased to announce their recently signed Agreement to collaborate with the highly regarded London School of Hygiene & Tropical Medicine.
- Collaboration with world-leading institute in development of new drugs
- Agreement surrounding use of 3D in vitro technologies to establish leishmania spp. infection in vitro models
- In vitro technology to aid in creating novel models of predictive drug efficacy to support development of new drugs for treatment of leishmaniasis
Under the Agreement, the organisations have begun a collaboration using 3D in vitro technologies to establish leishmania spp. infection in vitro models. These technologies, when integrated, could potentially offer a novel model for the in vitro screening of experimental drug compounds for anti-Leishmanial activity.
Leishmaniasis is a disease caused by leishmania, a parasite that is transmitted to humans through sand fly bites. Leishmaniasis affects people living in Asia, Africa, America and Europe manifesting as visceral (300,000 cases annually and 20,000 deaths), cutaneous (one million cases reported in the last five years) or mucocutaneous leishmaniasis. Over 300 million people in developing countries are at risk of leishmaniasis.
The London School of Hygiene & Tropical Medicine is a world-leading institute in the development of new drugs to treat leishmaniasis and many other diseases.
InvitroCue Executive Director, Dr Steven Fang commented: "We are very-pleased to be collaborating with a world class institute such as the London School of Hygiene & Tropical Medicine. We are especially excited in the potential they see in our technology for near term and future use."
"The Agreement provides us with a sense of validation for our technology and I look forward to updating shareholders with progress on further agreements and collaborations such as this in the near future."
About the London School of Hygiene & Tropical Medicine:
The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with more than 4,000 students and 1,000 staff working in over 100 countries. The School is one of the highest-rated research institutions in the UK, and among the world's leading schools in public and global health. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice.
About InvitroCue Ltd
InvitroCue Ltd (ASX:IVQ) is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.
Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ.
| ||
|
